VascuLink – Modelling the neurovascular unit by linking brain organoids to the blood-brain barrier
This four-year PhD project develops a next-generation human neurovascular unit-on-a-chip. We integrate our iPSC-derived blood-brain barrier (BBB) model with cortical organoids and electrophysiological readouts. Our goal is to build a human-relevant platform to study neurovascular dysfunction in alzheimer’s disease and accelerate preclinical drug development while reducing animal use.
VascuLink is a unique public-private partnership. The Neuro-immunology research group at Amsterdam UMC contributes expertise in BBB biology and iPSC-derived models (Elga de Vries' lab). UMC Utrecht adds knowledge on cortical organoids (lab of Elly Hol). NETRI provides organ-on-chip technology. Accure Therapeutics supports translational validation. hDMT strengthens standardisation of new approach methodologies. Proefdiervrij, Hersenstichting and Alzheimer Nederland ensure societal relevance and patient alignment within the BRAINS initiative.
As a PhD candidate, you enrol in the Graduate School of Amsterdam UMC.
Would you like to know more about the different phases within the PhD trajectory? You can read more about this on this page.
You develop and validate an advanced in vitro BBB model integrated with cortical brain organoids. You focus on modelling neurovascular dysfunction in alzheimer’s disease and testing BBB-restoring compounds.
Your work includes:
You collaborate closely with academic and industry partners and present your findings at consortium meetings and scientific conferences.
You are driven to advance translational neuroscience and reduce reliance on animal models. You combine technical expertise with perseverance and a collaborative mindset.
You have:
Experience with MEA technology, neuroimmunology or alzheimer’s disease models is a plus. Hepatitis B vaccination is mandatory and provided by Amsterdam UMC.
Watch this video with more information about joining Amsterdam UMC Research BV.
You join the Neuro-immunology research group within the department of Molecular Cell Biology and Immunology at Amsterdam UMC, location VUmc (O|2 building). The project is supervised by prof. dr. Elga de Vries and dr. Henrique Nogueira Pinto and embedded in Amsterdam Neuroscience.
This PhD project is carried out in close collaboration with the Department of Translational Neuroscience at UMC Utrecht, under supervision of prof. dr. Elly Hol. You will interact regularly with researchers in Utrecht and work across institutes within a strong national consortium.
You become part of a multidisciplinary team of approximately 30 researchers with expertise in neuroimmunology, bioengineering, stem cell biology and molecular neuroscience. The culture is collaborative and ambitious, with strong links to industry partners and a clear translational focus. This environment offers direct exposure to organ-on-chip development, iPSC technology and drug discovery for neurodegenerative diseases.
Amsterdam UMC Research BV supports non-profit scientific research. In doing so, we provide researchers with everything they need to excel. Our principal investigators (PIs) and project leaders offer support in the field of project management, finance and human resources. In medical scientific research projects, legal support is also provided.
Watch the video to find out more.
During the publication period, applications will be handled continuously. If the vacancy is filled, it will be closed prematurely.
If you have any questions about this position, please feel free to contact Elga de Vries, at he.devries@amsterdamumc.nl or Henrique Nogueira Pinto, at c.h.nogueirapinto@amsterdamumc.nl.
For more information about the application procedure, please contact Chey Edwards, recruitment advisor, at c.i.edwards@amsterdamumc.nl.
A reference check, screening and hiring assessment may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct).
Internal candidates will be given priority over external candidates in case of equal suitability.
Acquisition in response to this vacancy will not be considered.


